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Gastric adenomas are rare neoplastic growths characterized by localized polypoid proliferations of dysplastic
epithelium that tend to progress to infiltrating adenocarcinoma. Therefore, the identification of molecular
markers that could reliably recognize adenomas at risk of progression is advocated in the clinical management.
In this study we investigated, in a series of gastric adenoma specimens from an area at high risk of gastric
cancer, the relationship between clinicopathological characteristics of adenoma and Helicobacter pylori
infection, APC mutational status, and COX-2 and the down-stream enzyme mPGES1 expression. Helicobacter
pylori infection, detected in 24%, and 33% by histology and PCR analyses, respectively, did not show any
relationship with growth pattern, localization, size, dysplasia grade and presence of synchronous cancer.
Pathogenetic mutations of MCR region (codons 1269–1589) of the APC gene were detected only in one case
corresponding to a single, small size, low grade, H. pylori-negative adenoma. The expression of COX-2 largely
matched that of mPGES1. Both were overexpressed in 79% of cases showing a relationship with high-grade
dysplasia, size >10 mm and presence of a synchronous carcinoma. In conclusion, COX-2 may play a key role in
the development and progression of gastric adenoma and could be an attractive target in the management of
gastric adenoma at major risk of cancer development.
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introduction
Gastric adenomas are rare neoplastic growths characterized by
localized polypoid proliferation of dysplastic epithelium that
generally arise against a background of mucosal atrophy and
intestinal metaplasia [1]. Gastric adenomas tend to progress to
infiltrating adenocarcinoma and are associated with a higher
risk of adenocarcinoma elsewhere in the stomach [2–5]. Tumor
size and histological grading of dysplasia have been indicated as
prognostic markers [6]. Adenomas with high-grade dysplasia
progress to adenocarcinoma in the majority of cases while those
with low-grade dysplasia may persist unchanged or in a small
minority progress to cancer [7, 8]. The identification of
molecular markers that could reliably recognize adenomas at
risk of rapid progression may be helpful in the clinical
management of these patients.
Somatic mutations in the APC gene that tend to target
a gastric mutation cluster region (MCR) extending between
codons 1269 and 1589, are implicated in the pathogenesis of
fundic adenomas [9]. However, unlike APC mutations in the
colorectum [10, 11], a negative relationship between APC gene
mutations and the development of adenocarcinoma has been
noted, which agrees with the observation that fundic adenomas
of familial adenomatous polyposis (FAP) patients rarely
progress to cancer [9].
Cyclooxygenase-2 (COX-2), the rate limiting enzyme in the
conversion of arachidonic acid to prostaglandins, is implicated
in the progression of colorectal adenomas and FAP [12, 13]. The
biological effects of COX-2 are partly mediated through PGE2,
the product of microsomal prostaglandin (PG) E synthase 1
(mPGES1) [14]. COX-2 and mPGES1 expression is up-regulated
in gastric carcinoma as well as in gastric precancerous lesions
[15–19]. The expression of COX-2 in gastric mucosa seems to be
up-regulated by Helicobacter pylori infection, a well known
carcinogenetic factor according to Correa’s model [15, 16].
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There are numerous data in the literature concerning the
association between H. pylori and gastric cancer [20–24]. In
contrast, the role of bacterium in the development and
progression of gastric adenoma remains unclear.
In this study we investigated a series of gastric adenoma
specimens from an area at high risk for gastric cancer in
northern Italy. The aim was to analyse the relationship between
clinicopathological characteristics of gastric adenomas and the
presence of H. pylori infection, APC mutational status, and
expression of COX-2 and the downstream enzyme mPGES1.
patients and methods
pathological characterization
The study series consisted of 29 paraffin-embedded gastric adenoma cases.
The specimens were obtained during gastrectomy performed for
synchronous gastric cancer or by polypectomy performed during upper
endoscopy. For each case, sections of tumoral and peritumoral areas were
studied. The cases were grouped in three subsets according to the Vienna
classification [7]: low-grade adenoma/dysplasia, high-grade adenoma/
dysplasia and intramucosal carcinoma. Briefly, adenomas with low-grade
dysplasia showed elongated, hyperchromatic and crowded nuclei with mild
pseudostratification. Cribriforming architecture, marked glandular
crowding, full-thickness nuclear stratification, and /or severe cytologic
atypia were criteria for high-grade dysplasia. The adjacent non-tumoral
mucosa were evaluated after staining with hematoxylin and eosin, Giemsa
(for identification of H. pylori) and PAS/Alcian blue at pH 2.5 (for
evaluation of intestinal metaplasia). In non-adenomatous gastric mucosa the
presence of H. pylori, grade of inflammation, glandular atrophy, and
intestinal metaplasia were classified according to the up-dated Sydney
system [25]. Finally, synchronous carcinomas were classified according to
Lauren’s criteria [26].
immunohistochemistry
For each biopsy, 4-lm thick serial sections were cut from paraffin blocks,
mounted on acid-cleaned glass slides and heated at 55C for 60 min. Slides
were de-waxed and re-hydrated, then endogenous peroxidase activity was
inhibited by incubation with 3% H2O2 in methanol (20 min at room
temperature). To reduce non-specific background staining, slides were
incubated with 5% goat serum (15 min at room temperature). Finally, slides
were incubated with the appropriate primary antisera in a moist chamber
overnight at 4C. Immunohistochemistry for COX-2 and mPGES1 was
performed using specific antibodies to COX-2 (dilution 1:500; Santa Cruz
Biotechnology, Santa Cruz, CA) and mPGES1 (dilution 1:800; Santa Cruz
Biotechnology, Santa Cruz, CA). The avidin–biotin–peroxidase complex
procedure (ABC standard, Vector Laboratories, Burlingame, CA, USA) was
then performed. Peroxidase activity was detected with diaminobenzidine
(DAB) as the substrate. Finally, sections were weakly counterstained with
Harris’s hematoxylin and mounted. Two independent approaches were used
to confirm the specificity of the immunohistochemical signal: serial dilution
of the primary antibody until the signal disappeared; and the use of non-
immune rabbit IgG instead of primary antibody, which failed to reveal
relevant staining.
The intensity of the staining of both COX-2 and mPGES1 was estimated
on a scale from 0 (absent) to 4 (strong) and the area of positivity was
assessed by providing values of 1 (focal or <10%), 2 (10%–30%), 3 (30%–
50%), or 4 (>50%). Scoring was independently performed by two observers
(RC and AR) and in the case of any disagreement, consensus was reached by
direct discussion.
DNA extraction
Paraffin-embedded sections were collected on microscope slides. Tumor and
tumor-free mucosal areas were identified within 10 lm-thick deparaffinized
sections lightly counterstained with hematoxylin and microdissected into
1.5 ml polypropilene vials, using a hematoxylin and eosin-stained step
section from the same block as a guide. DNA extraction was performed as
previously reported [27].
analysis of the APC gene
Mutations in the APCMCR (codons 1269 to 1589) were determined by PCR
and direct sequencing. PCRs were performed by amplification of six partially
overlapping segments, using a ‘seminested’ amplification protocol (primers
available upon request). Sequencing was performed on an ABI 310 Genetic
Analyzer (Applied Biosystem). Only 16 cases yielded DNA quantitatively
and qualitatively sufficient for mutational analysis of the APC gene.
genetic analysis of H. pylori
The presence of the glmM gene was determined in DNA samples extracted
from normal and adenoma areas by semi-nested PCR and sequence analysis.
Unavailability of freshly-frozen specimens required ad hoc development of
PCR-based assays specifically designed for short H. pylori sequences
retrievable from paraffin-embedded samples. On the basis of sequence
alignments performed using the CLUSTAL W software, we designed primer
sets [F1 (59-TAACCGAAGACATGCGCTG-39) and F2 (59-
AGACATGCGCTGTGATGC-39) for a 144 base-pairs (bp) fragment; R (59-
CATGAAAGATTTCTTCAATCAATCGCT-39) for a 137 bp fragment]
targeting a conserved region of the glmM (ureC) gene. PCRs (conditions
available upon request) were performed in a GeneAmp PCR System 9700
thermal cycler (PE Applied Biosystems, Foster City, CA, USA). Amplified
fragments were visualized on a 3% agarose gel electrophoresis stained with
ethidium bromide. The PCR products were directly sequenced using an ABI
PRISM Big Dye Terminator v3.0 Cycle Sequencing Ready Reaction Kit
(Applied Biosystems, Foster City, CA, USA). Sequence variants were always
confirmed using independent DNA preparations.
statistical analysis
Data was analyzed using the SPSS package for Windows. The categorical
variables were analyzed using the v2 test or Fisher’s exact test. P <0.05 was
taken as level of significance.
results
The clinical characteristics of the 29 patients with adenomas are
shown in Table 1. Patients in the series were more frequently
males than females (69% versus 31%). The mean age was 68
years (range 50–82). Adenomas were prevalently flat and were
roughly equally distributed (45% and 55% in the proximal and
distal stomach, respectively). Size ranged from 3 to 15 mm with
most cases <10 mm (79%). The grade of dysplasia, evaluated
according to the Vienna classification, was high in 55% of the
cases and low in the remaining 45%.
The histological characteristics of the gastric mucosa
surrounding the adenomas in relation to the localization,
growth pattern, size, dysplasia grading of the adenomas and
presence of synchronous gastric cancer are reported in Table 2.
Gastric activity was higher in flat adenomas <10 mm and with
low-grade dysplasia than in polypoid adenomas >10 mm and
with high-grade dysplasia. Atrophy and intestinal metaplasia
were present in the mucosa adjacent to the adenomas in all cases
in which the size of the lesion was >10 mm. No significant
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difference was found between presence of atrophy and intestinal
metaplasia regarding growth pattern, dysplasia grade and
location of adenomas.
Helicobacter pylori status evaluated by histology and PCR
analysis targeting the H. pylori glmM gene sequence as an
indicator of the presence of H. pylori infection is shown in Table
3.Helicobacter pylori was detected in 24%, and 33% by histology
and PCR analyses respectively, and in 41% by combining the
two tests. Overall, the presence of H. pylori did not significantly
differ in relation to growth pattern, localization, size, dysplasia
grade of adenomas and presence of synchronous cancer.
The mutation status of MCR of the APC gene (codons 1269–
1589) and the immuhistochemical expression of COX-2 and
mPGES1 are reported in Table 4 and 5, respectively.
The mutation status of the MCR of the APC gene (codons
1269–1589) was assessed in 16/29 (55%) cases. Pathogenetic
mutations were detected in only one case (no. 17) that carried
a frameshift mutation (del G at codon 1322 with stop codon at
1413), not present in normal matched tissue (Table 4). The case
corresponded to a single, small size, low-grade adenoma that
wasH. pylori-negative at both the histological and the molecular
evaluation. No MCR sequence changes other than germline
polymorphisms of not pathological significance were detected in
the remaining cases: one case (no. 23) showed a novel germline
G>A variant at codon 1365 (G1365S), six of 16 (38%) cases had
the frequent G>A polymorphism at codon 1493 (Table 4).
The expression of COX-2 largely matched that of mPGES1.
Both were overexpressed in 23 out of 29 (79%) cases regardless
of histological and/or molecular evidence of H. pylori infection
(Table 5). Interestingly, COX2 and mPGES1 were more
frequently overexpressed in adenomas with high-grade dysplasia
(15/16), >10 mm in size (five out of six) and with synchronous
carcinoma (14/17). All synchronous adenocarcinomas strongly
expressed both COX-2 and mPGE2S1. COX-2 and mPGES1
expression tended to be stronger in the surface epithelium of
adenomas, in endothelial cells and in inflammatory
mononuclear cells within tumor stroma (Figure 1).
The relationship between clinicopathological characteristics,
COX-2 expression and H. pylori infection in single and
synchronous gastric adenoma is reported in Table 6. Only the
grade of adenoma dysplasia was significantly associated with the
presence of synchronous gastric adenocarcinoma (P = 0.02).
discussion
Gastric cancer still ranks as one of the most frequent and lethal
types of cancer worldwide with a survival rate at 5 years of less
Table 1. Clinical and pathological characteristics of the 29 gastric
adenomas
N (%)
Gender distribution
Male 20 (69)
Female 9 (31)
Mean age (range) 68 (50–82)
Adenoma localization
Proximal 13 (45)
Distal 16 (55)
Growth pattern
Flat 17 (59)
Polypoid 12 (41)
Size
<10 mm 23 (79)
‡10 mm 6 (21)
Grade of dysplasia
Low 13 (45)
High 16 (55)
Cancer association
Present 12 (41)
Absent 17 (59)
Table 2. Histological findings in the surrounding stomach in patients with gastric adenomas
Localization Growth pattern Size Dysplasia grade Synchronous cancer
Proximal
(n = 4)
Distal
(n = 25)
Flat
(n = 17)
Polypoid
(n = 12)
<10 mm
(n = 23)
‡10 mm
(n = 6)
Low
(n = 13)
High
(n = 16)
Present
(n = 17)
Absent
(n = 12)
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Activity 3 (75) 13 (52) 12 (71) 4 (33) 12 (52) 2 (33) 6 (46) 10 (63) 9 (53) 5 (42)
Gastric atrophy 4 (100) 18 (72) 14 (82) 8 (66) 16 (70) 6 (100) 10 (77) 12 (75) 11 (65) 11 (92)
Intestinal Metaplasia 3 (75) 18 (72) 13 (76) 8 (66) 15 (65) 6 (100) 10 (77) 11 (69) 11 (65) 10 (83)
Table 3. H. pylori status according to histological and molecular evaluation
Diagnosis Overall
(n = 29)
n (%)
Localization Growth pattern Size Dysplasia grade Synchronous cancer
Proximal
(n = 4)
Distal
(n = 25)
Flat
(n = 17)
Polypoid
(n = 12)
<10 mm
(n = 23)
>10 mm
(n = 6)
Low
(n = 13)
High
(n = 16)
Present
(n = 17)
Absent
(n = 12)
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Histology (H) 7 (24) 1 (25) 6 (24) 4 (24) 3 (25) 6 (26) 1 (17) 5 (38) 2 (13) 6 (35) 1 (8)
Genetic (G) 8 (33) 2 (50) 6 (24) 5 (29) 3 (25) 5 (22) 3 (50) 3 (23) 5 (31) 5 (29) 3 (25)
H + G 12 (41) 2 (50) 10 (40) 6 (35) 6 (50) 8 (35) 4 (67) 6 (46) 6 (38) 9 (53) 3 (25)
Genetic, RT-PCR detection of glmM gene.
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than 20% [28]. At present, prevention is likely to be the most
effective means of reducing the incidence of and the mortality
from this disease [29]. However, to be successful, this strategy
depends upon a better understanding of the etiologic factors
and the molecular mechanism underlying the carcinogenetic
process.
Gastric adenoma does not appear to represent the major
precursor of gastric adenocarcinoma; however, it may be
considered a more specific premalignant lesion than atrophic
gastritis alone [1, 30]. About 30% of the 890 cases of gastric
adenoma examined endoscopically at the National Cancer
Center Tokyo (Japan) were associated with cancerous changes
either within the adenoma or elsewhere in the stomach,
suggesting a similar underlying pathogenesis for adenoma and
carcinoma [31]. The risk of developing gastric cancer within
gastric adenoma appears to increase with the size of the lesions
even if relatively small adenomas can harbor infiltrating
adenocarcinoma [6, 32]. Overall, gastric cancer risk ranges
between 2.5% and 50% in a reported series of gastric adenomas
[5, 33–38]. In our study, comparing single adenomas with
adenomas synchronous to adenocarcinoma, we did not find any
significant difference regarding site, size and growth pattern of
adenoma. Only the grade of dysplasia was more frequent in
synchronous than in single adenoma (P <0.02) (Table 6). In
agreement with the Vienna classification [7], the grade of
dysplasia may be useful to assess the potential for adenoma
progression, indeed, 80% of adenomas with high-grade
dysplasia progress to adenocarcinoma whereas only 15% of
those with low-grade dysplasia progress to high grade or
adenocarcinoma [8]. Studies from Japan have suggested an
association between gastric adenomas and environmental type
metaplastic atrophic gastritis and/or H. pylori infection [39–41].
The incidence of atrophic gastritis in patients with gastric
adenoma is higher than in the general population [42]. Recently,
Lee et al. [43] found extensive metaplastic atrophic gastritis in
45% of the studied population.
The high incidence of atrophic gastritis might reflect the long
lastingH. pylori gastritis that, in turn, leads to a constant cellular
stress. However, Komoto et al. [40] found that H. pylori
infection was increased among patients with gastric adenomas
but the frequency of active H. pylori gastritis was not different
from that in controls. In our study, we found severe atrophic
gastritis, intestinal metaplasia and H. pylori infection in 30%,
70% and 41%, respectively. Both atrophy and intestinal
metaplasia were prevalently detected in adenoma with
synchronous carcinoma (Table 6). It is likely that severe atrophy
with loss of acid production does not favour the growth of H.
pylori that may be no longer detectable, even though it initially
induced the mucosal damage.
At present, there are no definite histological or clinical
markers to identify the subgroup of adenomas progressing to
adenocarcinoma. Therefore, expression profiling of genes in
mucosal bioptic samples may contribute to clinical practice and
may promote objective criteria for intervention, such as
endoscopic mucosal resection.
In this study we aimed to see what relationship existed
between clinicopathological findings of gastric adenoma,
H. pylori infection, APC mutations and COX-2 and the down
stream mPGES1 expression. Our data did not reveal any
significant relationship between APC germline mutation and
Table 4. Molecular analysis of MCR region (codons 1269–1589) of
the APC gene in gastric adenomas
Case no. APC (MCR region)
1 T1493T, nt 4479 (G>A), Thr/Thr
2 NA
3 T1493T, nt 4479 (G>A), Thr/Thr
4 NA
5 WT
6 T1493T, nt 4479 (G>A), Thr/Thr
7 NA
8 NA
9 NA
10 NA
11 WT
12 WT
13 WT
14 T1493T, nt 4479 (G>A), Thr/Thr
15 NA
16 T1493T, nt 4479 (G>A), Thr/Thr
17 Del G. Cod.1322 nt 3964, codon stop 1414
18 WT
19 WT
20 NA
21 T1493T, nt 4479 (G>A), Thr/Thr
22 NA
23 G1365S, nt 4479 (G>A, Gly/Ser)
24 NA
25 NA
26 NA
27 WT
28 NA
29 NA
NA, tissue not available; WT, wild type.
Table 5. COX-2 and mPGES1 expression in gastric adenomas in relation to clinicopathological characteristics of gastric adenomas
COX-2/ mPGES1 Overall
(n = 29)
n (%)
Localization Growth pattern Size Dysplasia grade Synchronous cancer
Proximal
(n = 13)
Distal
(n = 16)
Flat
(n = 17)
Polypoid
(n = 12)
<10 mm
(n = 23)
>10 mm
(n = 6)
Low
(n = 13)
High
(n = 16)
Present
(n = 12)
Absent
(n = 17)
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Absent 6 (21) 3 (23) 3 (19) 4 (23) 2 (16) 5 (22) 1 (17) 5 (38) 1 (6) 3 (25) 3 (18)
Mild 12 (41) 4 (31) 8 (50) 7 (41) 5 (42) 11 (48) 1 (17) 6 (46) 6 (37) 5 (42) 7 (41)
Strong 11 (38) 6 (46) 5 (31) 6 (35) 5 (42) 7 (30) 4 (76) 2 (16) 9 (57) 4 (33) 7 (41)
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gastric adenoma, which agrees with the observation that APC is
not implicated in the malignant transformation of gastric
adenoma [9].
The data concerning the expression of COX-2 and the
downstream enzyme mPGES1 are of particular interest. Indeed,
we found both COX-2 and mPGES1 overexpressed in 79% of
our cases particularly in adenomas with high-grade dysplasia
(15/16), >10 mm in size (five of six) and with synchronous
carcinoma (14/17). COX-2 expression is one of the earliest and
most frequent molecular alterations involved in gastric cancer
[15, 16]. COX-2 is implicated in carcinogenesis by several
mechanisms, i.e. inhibition of apoptosis, stimulation of cell
proliferation, angiogenesis, mutagenic activity and signal
transduction regulation [44]. Currently, while numerous
reports concerning the role of COX-2 in gastric tumorigenesis
are present in the literature, only few data are available on
COX-2 expression in gastric adenomas.
In conclusion, our data could suggest that COX-2 may play
a role in the development and progression of gastric adenoma.
Thus, COX-2 could be an attractive target in the management of
gastric adenoma at major risk of cancer development.
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